To fight cancer, we should study T cells more

To fight cancer, we should study T cells more

by Dr. Adam Rochussen

Life & Natural Systems Medicine & Health MJCDiseases and disordersMJCMImmunology
🎙 Dr. Adam Rochussen 👥 2K 📅 February 17, 2026 ⏱ 18 min 👁 183 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

T cellscancerimmunotherapyCAR Tcheckpoint inhibitors

Summary

In this talk, Dr. Adam Rochussen, a postdoctoral researcher at the Salk Institute, argues that fundamental research on T cells is crucial for developing better cancer immunotherapies. He begins by explaining the challenge of cancer treatment: killing cancer cells while sparing healthy ones. He contrasts surgery, radiation, chemotherapy, and hormone therapy with immunotherapy, which leverages the body’s own T cells. He describes how T cells recognize and kill cancer cells via their T cell receptors, and how tumors create immunosuppressive microenvironments to evade attack. He highlights the discovery of immune checkpoint receptors CTLA-4 and PD-1, which act as brakes on T cells, and how blocking them with antibodies (checkpoint inhibitors) has revolutionized cancer treatment, citing a 2024 VA study showing significant life-year gains. He then discusses CAR T cell therapy, which involves engineering patients’ T cells to target cancer, but notes its limitations against solid tumors. He argues that understanding basic T cell biology can improve CAR T cell efficacy. He presents two examples from his PhD: first, he found that knocking out CDC42 in T cells unexpectedly boosted their cancer-killing ability due to transcriptional adaptation, a compensatory response to CRISPR-induced DNA damage. Second, he discovered a novel protein isoform that regulates dynein-mediated polarized secretion, essential for T cell killing. He suggests these findings could be leveraged to enhance CAR T cell therapy. He concludes by emphasizing the importance of fundamental research and the ethos of the Cambridge Society for the Application of Research.

244 words

Critical Evaluation

Value of the Information & Strength of the Argument

The talk provides valuable insights into the rationale for studying T cell biology to improve cancer immunotherapy. The argumentation is solid, building from first principles of cancer treatment specificity to the promise of immunotherapy, then to specific examples from the speaker’s research. The speaker effectively explains complex concepts (e.g., T cell signaling, transcriptional adaptation) in an accessible manner. The use of his own unpublished data adds novelty, though it limits verifiability. The argument that fundamental research can lead to therapeutic advances is well-supported by historical examples (checkpoint inhibitors).

Scientific Rigor, Source Quality, Title Accuracy

The talk demonstrates scientific rigor, with references to key publications (e.g., the 1996 CTLA-4 paper, the 2018 Nobel Prize, a 2024 VA study). The speaker clearly distinguishes between published work (his JCB paper) and unpublished findings. The title accurately reflects the content. The talk is well-structured and the speaker is transparent about the limitations of current therapies. No comments were provided for analysis.

166 words

Title / Content Match

The title accurately reflects the core message: the importance of fundamental T cell research for cancer therapy.

Quality & Reliability

8/10

The speaker is a PhD holder in T cell biology, presenting his own research and referencing established literature (e.g., 1996 CTLA-4 paper, 2018 Nobel Prize, 2024 VA study). The content is scientifically accurate and well-structured, though it is a single expert's perspective.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • Journal of Cell Biology publication on CDC42 knockout — Speaker's own research on transcriptional adaptation in T cells.
  • 1996 paper on CTLA-4 blockade — Original mouse data showing tumor regression with anti-CTLA-4 antibody.
  • 2018 Nobel Prize in Physiology or Medicine — Awarded for discovery of cancer therapy by inhibition of negative immune regulation.
  • 2024 US National Veterans Health Administration study — Study showing checkpoint inhibitors led to ~16,000 life-years gained.

Concurring Sources

  • Leach et al. (1996) Science — Original paper demonstrating CTLA-4 blockade in mice.
  • Ribas & Wolchok (2018) Science — Review on cancer immunotherapy and checkpoint blockade.

Contribution & Novelties

The talk presents the speaker’s original research on CDC42 knockout and transcriptional adaptation, and a novel protein isoform regulating dynein, both unpublished at the time. These findings could inform new strategies to enhance CAR T cell therapy. The talk also emphasizes the value of fundamental cell biology in driving therapeutic innovation.

Pour aller plus loin :

97 words

Radar Profile

The radar profile shows high scores in quality and reliability, with moderate scores in quantity and technical level. This indicates a well-supported, expert-led talk with a focus on depth over breadth.

Reliability 8/10